Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin vs Hydrochlorothiazide for Sympathetic Overactivity in T2DM and Hypertension
NCT03640221Phase 4Withdrawn
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Sep 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ertugliflozin in type 2 diabetes mellitus (T2DM), sponsored by Cedars-Sinai Medical Center. Planned start Sep 2018; status: withdrawn.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03640221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03640221.